Brief: Zai Lab Reports NDA Acceptance Of Sulbactam-Durlobactam (SUL-DUR) For Infections Caused By Acinetobacter Baumannii In China By NMPA
Feb 22 (Reuters) - Zai Lab Ltd 9688.HK :
* ZAI LAB LTD: NDA ACCEPTANCE OF SULBACTAM-DURLOBACTAM
(SUL-DUR)
FOR INFECTIONS CAUSED BY ACINETOBACTER BAUMANNII IN CHINA BY
NMPA
Source text for Eikon: ID:nGNX41c9hL
Further company coverage: 9688.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zai Lab
See all newsBrief: Zai Lab Says ZL-1503 Was Well Tolerated With No Serious Adverse Events
Brief: Zai Lab Agrees To Issue To Investors Aggregate Of 11.3 Million ADSs
Zai Lab's Hong Kong shares hit three-month high on quarterly revenue beat
Brief: U.S. FDA Grants Orphan Drug Designation To Zai Lab’S Dll3-Targeting Adc Zocilurtatug Pelitecan (Zoci) For The Treatment Of Neuroendocrine Carcinomas (Necs)
Brief: Goldman Sachs Group's Long Position In Zai Lab Decreases On May 14, HKEX Filing Shows